Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Preference of AZARGA vs COSOPT in Glaucoma/OHT
NCT01471158Phase 4
Key facts
- Status
- Completed
- Start
- Sep 2010
- Primary completion
- May 2011
- Countries
- 1
- Sponsor
- Alcon Inc.
- Modality
- Small Molecules
- Drugs
- Azorga
- Conditions
- open-angle glaucoma (OAG)ocular hypertension
01
Overview
Phase 4, randomised, single-blind trial of Azorga in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Alcon Inc. Primary endpoint: Ocular Discomfort. Started Sep 2010; status: completed.
02
Design
2 arms- Study design
- RandomizedSingle-blind
Azarga then Cosopt
Azarga on Day 1, Cosopt on Day 2
Cosopt then Azarga
Cosopt on Day 1, Azarga on Day 2
03
Who it enrols
Patients with ocular hypertension or open-angle glaucoma on a stable IOP-lowering regimen, excluding those with asthma, COPD, corneal dystrophies, or severe allergic rhinitis.
04
Endpoints
Primary
Ocular Discomfort
Beyond the preview
Go deeper on NCT01471158.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01471158.